Enlivex Ltd.

ENLV
About the company

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.

Country: IsraelPrice: $1.19Market Cap: $1.8M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

3 / 11

NEUTRAL / FAIL

Median fair value

$151.24

+12609.2% vs price

Models with upside

1 / 17

Positive margin of safety

Key risk

No clean pass — all 8 investors flag at least one growth criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedPASSFAILPASSNEUTRALFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety+99.2%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-25

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Growth0% pass✓ 1✗ 12▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)P/E 0.0x (growth N/A)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthN/A (no inventory)
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency1/14 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth
      ✗Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag ENLV's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities193.24
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-13.2x, D/EBITDA=N/A (D&A unavailable)
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Cash Flow10% pass✓ 1✗ 11▾

      9 of 10 flag ENLV's cash flow — Buffett, Lynch, Piotroski +6 more

      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      FCF Positive and Growing$-10.5M
      ✗LynchPositive and growing
      Operating Cash Flow$-10.4M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-0.45%, ROA=53.10%
      ✗PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldP/E=0.0x, FCF Yield=-575.1%
      ✓PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/14 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-18.2%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/14 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-10.5M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-575.07%; #4361/4519 (top 96.5%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Profitability13% pass✓ 9✗ 26▾

      14 of 16 flag ENLV's profitability — Graham, Buffett, Lynch +11 more

      Positive EPS (10 years)2/15 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)1/15 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-33.6%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)P/E 0.0x (growth N/A)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE63.9%
      ✓Lynch> 15%
      EBIT / Enterprise ValueN/A (EV <= 0)
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-0.9%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets53.10%
      ✓PiotroskiROA > 0
      ROA Change YoY-54.23% -> 53.10% (delta: +107.32%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-0.45%, ROA=53.10%
      ✗PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity63.9%
      ✓Dreman> 12%
      Margin of SafetyP/E=0.0x, P/B=0.0x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-32.1% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency1/14 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue
      ✗Ackman>= 15%
      Net Income / Shareholders Equity63.9%
      ✓Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization+67771.72%; #6/6340 (top 0.1%)
      ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity+63.85%; #161/5226 (top 3.1%)
      ✓AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.4548; #4878/5884 (top 82.9%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years1/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts15% pass✓ 2✗ 11▾

      Split decision: 11 FAIL · 3 NEUTRAL · 2 PASS

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (2/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 4)✗DremanFAIL (4/11)✓MungerPASS (2/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (0/6)✗MarksFAIL (1/5)✗AckmanFAIL (1/9)✗TempletonFAIL (3/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
    • Valuation23% pass✓ 14✗ 14▾

      10 of 13 flag ENLV's valuation — Graham, Lynch, Greenblatt +7 more

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.0x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)P/E 0.0x (growth N/A)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise ValueN/A (EV <= 0)
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-0.9%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS0.0x
      ✓Dreman< 12x✓Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share0.0x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessP/E=0.0x
      ✓MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldP/E=0.0x, FCF Yield=-575.1%
      ✓PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/E=0.0x, P/B=0.0x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low184% of trailing low ($0.65)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization+67771.72%; #6/6340 (top 0.1%)
      ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+1061.3662; #22/6449 (top 0.3%)
      ✓AsnessTop 30% of eligible cross-section
      Price / Diluted EPS0.0x
      ✓NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share0.03x
      ✓SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-575.07%; #4361/4519 (top 96.5%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-91.75%; #6020/6202 (top 97.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag ENLV's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio193.24
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)
      ✗Buffett> 10%
      ROIC - WACC
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-0.9%
      ✗Greenblatt> 25%
      Current Ratio Change YoY6.84 -> 193.24
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities193.24
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($1.8M)
    Revenue: N/A
    Net Income: $1.2B+8329.2% YoY

    Financial Snapshot

    Operating Margin--
    Return on Equity63.9%
    Debt / Equity--
    Current Ratio193.24
    EPS (Diluted)$25.48

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    MetricFY 2025
    Sources
    • 20-F · 2026-03-25
    FY 2024
    Sources
    • 20-F · 2025-04-30
    FY 2023
    Sources
    • 20-F · 2024-04-30
    FY 2022
    Sources
    • 20-F · 2024-04-30
    FY 2021
    Sources
    • 20-F · 2022-04-29
    Market Cap$1.8Mcurrent$26.0Mest.$52.1Mest.$80.7Mest.$97.9Mest.
    Revenue----------
    Operating Income-$15.0M↑5%-$15.9M↑46%-$29.4M↓14%-$25.8M↓34%-$19.3M
    Net Income$1.2B↑8329%-$15.0M↑48%-$29.1M↑6%-$31.1M↓115%-$14.5M
    EPS (Diluted)$25.48↑3590%$-0.73↑53%$-1.56↑8%$-1.69↓109%$-0.81
    Gross Margin—————
    Operating Margin—————
    ROE63.9%↑200%-63.6%↑34%-96.6%↓77%-54.6%↓221%-17.0%
    Total Debt----------
    Shareholders' Equity$1.9B↑8103%$23.6M↓22%$30.1M↓47%$56.8M↓33%$85.0M
    Current Ratio193.24↑2724%6.84↑23%5.57↓30%7.92↓57%18.32
    Debt / Equity—————
    Operating Cash Flow-$10.4M↑20%-$13.0M↑45%-$23.5M↑2%-$24.0M↓37%-$17.5M
    Free Cash Flow-$10.5M↑20%-$13.1M↑45%-$23.8M↑26%-$32.1M↓67%-$19.2M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    ENLV vs Peers — Financial Grading

    RevenueN/A
    Net Income$1.2BMedian
    ROE63.9%Top 25%
    D/E—
    Op. Margin—
    Curr. Ratio193.24Top 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11